Cover Image
市場調查報告書

生物可吸收支架:醫療設備的開發平台評估

Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016

出版商 GlobalData 商品編碼 347100
出版日期 內容資訊 英文 131 Pages
訂單完成後即時交付
價格
Back to Top
生物可吸收支架:醫療設備的開發平台評估 Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016
出版日期: 2016年11月01日 內容資訊: 英文 131 Pages
簡介

本報告提供生物可吸收支架的開發中產品調查分析,以各開發階段比較分析為焦點,提供開發中產品的開發中主要企業,進行中的臨床試驗相關資訊等系統性資訊。

第1章 目錄

第2章 簡介

  • 生物可吸收支架概要

第3章 開發中的產品

  • 生物可吸收支架 - 開發中產品:各開發階段
  • 生物可吸收支架 - 開發中產品:各地區
  • 生物可吸收支架 - 開發中產品:各法規
  • 生物可吸收支架 - 開發中產品:各核准預定日
  • 生物可吸收支架 - 進行中的臨床試驗

第4章 生物可吸收支架 - 正在開發的開發中產品:各企業

  • 生物可吸收支架企業 - 開發中產品:各開發階段
  • 生物可吸收支架 - 開發中產品:各開發階段

第5章 生物可吸收支架企業與產品概要

  • Abbott Vascular Inc.
  • AlviMedica Medical Technologies Inc.
  • Amaranth Medical, Inc.
  • Arterius Ltd
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Cardionovum GmbH
  • Elixir Medical Corporation
  • HangZhou HuaAn Biotechnology Co., Ltd.
  • Icon Interventional Systems, Inc.
  • 日本支架科技
  • Lepu Medical Technology (Beijing) Co., Ltd.
  • Medlogics Device Corporation
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • NanoCoeur, Inc.
  • Northwestern University
  • OrbusNeich
  • REVA Medical, Inc.
  • S3V Vascular Technologies
  • Shanghai MicroPort Medical (Group) Co., Ltd.
  • Tepha, Inc.
  • Terumo Corporation
  • Xenogenics Corporation
  • Zorion Medical

第6章 生物可吸收支架 - 最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0235EPD

GlobalData's Medical Devices sector report, "Bioabsorbable Stents (BAS) - Medical Devices Pipeline Assessment, 2016" provides an overview of Bioabsorbable Stents (BAS) currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents (BAS) pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Bioabsorbable Stents (BAS) under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Bioabsorbable Stents (BAS) and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Bioabsorbable Stents (BAS) under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Bioabsorbable Stents (BAS) Overview

3. Products under Development

  • 3.1. Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • 3.2. Bioabsorbable Stents (BAS) - Pipeline Products by Territory
  • 3.3. Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
  • 3.4. Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
  • 3.5. Bioabsorbable Stents (BAS) - Ongoing Clinical Trials

4. Bioabsorbable Stents (BAS) - Pipeline Products under Development by Companies

  • 4.1. Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
  • 4.2. Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development

5. Bioabsorbable Stents (BAS) Companies and Product Overview

  • 5.1. Abbott Vascular Inc. Company Overview
    • 5.1.1. Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Amaranth Medical, Inc. Company Overview
    • 5.2.1. Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Arterius Ltd Company Overview
    • 5.3.1. Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Biosten, LLC Company Overview
    • 5.4.1. Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. Biotronik SE & Co. KG Company Overview
    • 5.5.1. Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Boston Scientific Corporation Company Overview
    • 5.6.1. Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Cardionovum GmbH Company Overview
    • 5.7.1. Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. HangZhou HuaAn Biotechnology Co., Ltd. Company Overview
    • 5.8.1. HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Icon Interventional Systems, Inc. Company Overview
    • 5.9.1. Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Japan Stent Technology Co., Ltd. Company Overview
    • 5.10.1. Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Kyoto Medical Planning Co., Ltd. Company Overview
    • 5.11.1. Kyoto Medical Planning Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Lifetech Scientific (Shenzhen) Co., Ltd. Company Overview
    • 5.12.1. Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Medlogics Device Corporation Company Overview
    • 5.13.1. Medlogics Device Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. Meril Life Sciences Pvt. Ltd. Company Overview
    • 5.14.1. Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. MicroPort Scientific Corporation Company Overview
    • 5.15.1. MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. NanoCoeur, Inc. Company Overview
    • 5.16.1. NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. North Carolina State University Company Overview
    • 5.17.1. North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Northwestern University Company Overview
    • 5.18.1. Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. OrbusNeich Company Overview
    • 5.19.1. OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Pegasus Therapeutics, Llc Company Overview
    • 5.20.1. Pegasus Therapeutics, Llc Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. REVA Medical, Inc. Company Overview
    • 5.21.1. REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. S3V Vascular Technologies Company Overview
    • 5.22.1. S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. Shanghai MicroPort Medical Group Co Ltd Company Overview
    • 5.23.1. Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. Tepha, Inc. Company Overview
    • 5.24.1. Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. VasoTech Inc. Company Overview
    • 5.25.1. VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Xenogenics Corporation Company Overview
    • 5.26.1. Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview

6. Bioabsorbable Stents (BAS)- Recent Developments

  • 6.1. Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer
  • 6.2. Sep 28, 2016: Nevada Heart And Vascular Center Announces Partnership With Desert Springs Hospital Offering First-Of-Its-Kind Naturally Dissolving Heart Stent For Patients With Coronary Artery Disease
  • 6.3. Aug 30, 2016: MPSC Announces 2016 Interim Results
  • 6.4. Aug 17, 2016: Fully Dissolving Stent Revolutionizes Heart Disease Treatment
  • 6.5. Aug 08, 2016: DMC Heart Hospital Offers First-Of-Its-Kind Naturally Dissolving Heart Stent To Patients With Coronary Artery Disease
  • 6.6. Aug 02, 2016: REVA Completes Submission of CE Mark Application
  • 6.7. Jul 29, 2016: Sutter Health advances cardiovascular service by offering first-of-its-kind fully dissolving heart stent in Bay Area and Sacramento
  • 6.8. Jul 29, 2016: REVA Medical: Quarter Ended 30 June 2016
  • 6.9. Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016
  • 6.10. Jul 27, 2016: St. John Hospital & Medical Center Implants First Dissolving Heart Stent
  • 6.11. Jul 26, 2016: New Heart Device Trialed at Mercy Wins FDA Approval
  • 6.12. Jul 25, 2016: INTEGRIS Heart Hospital Implants First-of-its-kind Naturally Dissolving Heart Stent in Patient with Coronary Artery Disease
  • 6.13. Jul 14, 2016: St. Elizabeth's Medical Center Becomes First Hospital in New England to Implant Dissolvable Heart Stent
  • 6.14. Jul 14, 2016: Health Canada Approves Abbott's Absorb Bioresorbable Stent, The First Fully Dissolving Heart Stent
  • 6.15. Jul 13, 2016: Boston Scientific Elects Yoshiaki Fujimori to Board of Directors
  • 6.16. Jul 12, 2016: Good Samaritan Hospital First on the West Coast to Offer Naturally Dissolving Heart Stent to Patients with Coronary Artery Disease
  • 6.17. Jul 08, 2016: University Hospitals Case Medical Center cardiologists first to implant Abbott Absorb Stent in Midwest
  • 6.18. Jul 05, 2016: FDA approves first absorbable stent for coronary artery disease
  • 6.19. Jul 05, 2016: Arizona patient will receive first U.S.-approved fully dissolving heart stent
  • 6.20. Jun 08, 2016: Boston Scientific Announces Restructuring Program to Support Long-Term Growth and Innovation
  • 6.21. Jun 06, 2016: Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold
  • 6.22. Jun 06, 2016: Amaranth Medical Completes Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold
  • 6.23. Jun 03, 2016: LEPUCARE established in India
  • 6.24. May 18, 2016: Amaranth Medical On Track to Complete Enrollment in RENASCENT-II Study of 120-Micron APTITUDE Sirolimus-Eluting Bioresorbable Scaffold in May
  • 6.25. May 18, 2016: REVA Sponsors Symposium at EuroPCR 2016
  • 6.26. May 17, 2016: REVA Releases Positive Clinical Results for Fantom
  • 6.27. May 11, 2016: Elixir Medical to Showcase the Next Generation Bioresorbable Novolimus Eluting Coronary Scaffold System DESolve CX at EuroPCR 2016
  • 6.28. May 11, 2016: Elixir Medical to Showcase the Next Generation Bioresorbable Novolimus Eluting Coronary Scaffold System AMITY at EuroPCR 2016
  • 6.29. May 10, 2016: REVA to Present at EuroPCR 2016
  • 6.30. Apr 01, 2016: MicroPort and Yizheng Municipal Government Establishes "Shanghai-Yizheng Healthcare Cooperation Project"
  • 6.31. Mar 23, 2016: MicroPort Signs Cooperation Agreement with Beijing Weimai Medical Device
  • 6.32. Mar 15, 2016: Abbott's Absorb, the First Fully Dissolving Heart Stent, Earns Positive Review by FDA Advisory Committee
  • 6.33. Feb 23, 2016: REVA Achieves Target Patient Enrollment in FANTOM II Trial
  • 6.34. Feb 10, 2016: REVA Announces Clinical Enrollment Progress and Anticipated $11.4 Million Cash Receipt
  • 6.35. Jan 19, 2016: REVA Hires Richard Kimes as SVP of Operations

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Table 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
  • Table 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
  • Table 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
  • Table 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
  • Table 6: Bioabsorbable Stents (BAS) Companies - Pipeline Products by Stage of Development
  • Table 7: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Table 8: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: Absorb GT1 Bioresorbable Vascular Scaffold - Product Status
  • Table 10: Absorb GT1 Bioresorbable Vascular Scaffold - Product Description
  • Table 11: Second Generation Bioresorbable Vascular Scaffold - Product Status
  • Table 12: Second Generation Bioresorbable Vascular Scaffold - Product Description
  • Table 13: Abbott Vascular Inc. - Ongoing Clinical Trials Overview
  • Table 14: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Bioresorbable Vascular Scaffold, in the Treatment of Subjects with de Novo Native Coronary Artery Lesions in Chinese Population
  • Table 15: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold In the Treatment of Subjects with De Novo Native Coronary Artery Lesions
  • Table 16: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions
  • Table 17: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System (BVS EECSS) in the Treatment of Patients with de Novo Native Coronary Artery Lesions
  • Table 18: Absorb GT1 Bioresorbable Vascular Scaffold - A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Subjects with Ischemic Heart Disease Caused by de Novo Native Coronary Artery Lesions: ABSORB II Randomized Controlled Trial
  • Table 19: Absorb GT1 Bioresorbable Vascular Scaffold - A Continuation in the Clinical Evaluation of the Abbott Vascular Everolimus-Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de Novo Native Coronary Artery Lesions: ABSORB EXTEND Clinical Investigation
  • Table 20: Absorb GT1 Bioresorbable Vascular Scaffold - A Multicenter Prospective Natural History Study Using Multimodality Imaging in Patients with Acute Coronary Syndromes - PROSPECT II (Natural History Study), Combined with a Randomized, Controlled, Intervention Study - PROSPECT ABSORB (Randomized Trial)
  • Table 21: Absorb GT1 Bioresorbable Vascular Scaffold - A Prospective Evaluation of a Standardized Strategy for the Use of Bioresorbable Vascular Scaffold in ST-segment Elevation Myocardial Infarction -The BVS STEMI STRATEGY-IT Registry
  • Table 22: Absorb GT1 Bioresorbable Vascular Scaffold - A Prospective, Randomized Trial of Synergy Bioresorbable Polymer Coated Stents Versus Absorb Bioresorbable Backbone Stents in Patients Undergoing Coronary Stenting (ISAR-RESORB)
  • Table 23: Absorb GT1 Bioresorbable Vascular Scaffold - A Randomized Comparison of Clinical Outcomes Between Everolimus-eluting Bioresorbable Vascular Scaffold versus Everolimus-eluting Metallic Stent in Long Coronary Lesions
  • Table 24: Absorb GT1 Bioresorbable Vascular Scaffold - A Randomized Controlled Comparison of Optical Coherence Tomography Guidance and Angiography-only Guidance for Percutaneous Coronary Intervention with Bioresorbable Vascular Scaffold
  • Table 25: Absorb GT1 Bioresorbable Vascular Scaffold - Absorb Bioresorbable Scaffold versus Drug Coated Balloon for Treatment of In-Stent-Restenosis
  • Table 26: Absorb GT1 Bioresorbable Vascular Scaffold - ABSORB Bioresorbable Scaffold versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis
  • Table 27: Absorb GT1 Bioresorbable Vascular Scaffold - ABSORB III RCT Pharmacokinetics (PK) Sub-study
  • Table 28: Absorb GT1 Bioresorbable Vascular Scaffold - Amsterdam Investigator-initiated Absorb Strategy All-comers Trial (AIDA Trial) - A Clinical Evaluation Comparing the Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold Strategy Versus the XIENCE Family (XIENCE PRIME or XIENCE Xpedition) Everolimus Eluting Coronary Stent Strategy in the Treatment of Coronary Lesions in Consecutive All-comers
  • Table 29: Absorb GT1 Bioresorbable Vascular Scaffold - Bifurcation ABSORB OCT Trial
  • Table 30: Absorb GT1 Bioresorbable Vascular Scaffold - Clinical Study on Absorb Polylactic, Reabsorbable Coronary Scaffold (RAI)
  • Table 31: Absorb GT1 Bioresorbable Vascular Scaffold - Comparison Between SYNERGY Versus Bioresorbable Vascular Scaffold (BVS) ABSORB Neointimal Formation Assessed by (Optical Coherence Tomography) OCT and Coronary Angioscopy (CAS) Evaluation (The ENHANCE Study - Endothelial Healing Assessment With Novel Coronary Technology)
  • Table 32: Absorb GT1 Bioresorbable Vascular Scaffold - Comparison of a Paclitaxel-coated Balloon Without Stent Implantation Against an Everolimus-eluting Bioresorbable Scaffold for Treatment of Stable Coronary Artery Disease: A Prospective Randomized Study Using Optical Coherence Tomography
  • Table 33: Absorb GT1 Bioresorbable Vascular Scaffold - Comparison of the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold System with a Drug- Eluting Metal Stent (XienceTM) in Acute ST-Elevation Myocardial Infarction
  • Table 34: Absorb GT1 Bioresorbable Vascular Scaffold - Complex Bifurcation Lesions - A Randomized Comparison Between the AXXESS Device in Combination with Absorb BVS, and Modified T Stenting with Absorb BVS: An OCT Study
  • Table 35: Absorb GT1 Bioresorbable Vascular Scaffold - Comprehensive Imaging and Interventional Therapy Studies for Arteriogenic Erectile Dysfunction and Lower Urinary Tract Symptoms - A Multi-modality, Multi-specialty Collaborative Study (PERFECT Program)
  • Table 36: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents for Diffuse Long Coronary Artery Disease
  • Table 37: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffold System in the Treatment of Cardiac Allograft Vasculopathy in Heart Transplant Recipients: A Prospective Multicenter Pilot Study
  • Table 38: Absorb GT1 Bioresorbable Vascular Scaffold - Everolimus-eluting Bioresorbable Vascular Scaffolds Versus Everolimus-eluting Stents in Patients with Diabetes Mellitus
  • Table 39: Absorb GT1 Bioresorbable Vascular Scaffold - German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-Eluting Bioresorbable Vascular Scaffold System in Patients with Coronary Artery Stenosis
  • Table 40: Absorb GT1 Bioresorbable Vascular Scaffold - Impact of Vascular Reparative Therapy on Vasomotor Function and Myocardial Perfusion: A Randomized H215O PET/CT Study
  • Table 41: Absorb GT1 Bioresorbable Vascular Scaffold - Intracoronary Scaffold Assessment a Randomized Evaluation of Absorb in Myocardial Infarction (ISAR-Absorb MI): A Prospective, Randomized Trial of BVS Veruss EES in Patients Undergoing Coronary Stenting for Myocardial Infarction
  • Table 42: Absorb GT1 Bioresorbable Vascular Scaffold - Italian Diffuse/Multivessel Disease ABSORB Prospective Registry Under the Auspices of Societa Italiana di Cardiologia Invasive-GISE (IT-DISAPPEARS)
  • Table 43: Absorb GT1 Bioresorbable Vascular Scaffold - Optimal Lesion Preparation with Non-compliant Balloons for the Implantation of Bioresorbable Vascular Scaffolds (BVS) (OPRENBIS Study)
  • Table 44: Absorb GT1 Bioresorbable Vascular Scaffold - Performance of Bioresorbable Scaffold in Primary Percutaneous Intervention of ST Elevation Myocardial Infarct (BVS in STEMI)
  • Table 45: Absorb GT1 Bioresorbable Vascular Scaffold - Real World Advanced Experience of Bioresorbable Scaffold by Smart Angioplasty Research Team (SMART REWARD)
  • Table 46: Absorb GT1 Bioresorbable Vascular Scaffold - Safety and Feasibility of Bioabsorbable Everolimus-Eluting Stents for Patients with Internal Pudendal Artery-related Arteriogenic Erectile Dysfunction (PERFECT-ABSORB)
  • Table 47: Absorb GT1 Bioresorbable Vascular Scaffold - Strut Coverage with SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction: An Intracoronary Optical Coherence Tomography Randomized Study
  • Table 48: Amaranth Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 49: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Product Status
  • Table 50: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Product Description
  • Table 51: FORTITUDE Scaffold - Product Status
  • Table 52: FORTITUDE Scaffold - Product Description
  • Table 53: MAGNITUDE Scaffold - Product Status
  • Table 54: MAGNITUDE Scaffold - Product Description
  • Table 55: Next Generation FORTITUDE Scaffold - Product Status
  • Table 56: Next Generation FORTITUDE Scaffold - Product Description
  • Table 57: Amaranth Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 58: FORTITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - European Trial
  • Table 59: Next Generation FORTITUDE Scaffold - Amaranth Endovascular Study of a Drug-eluting Bioresorbable Coronary Scaffold
  • Table 60: APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial II
  • Table 61: MAGNITUDE Scaffold - Clinical Study of Fourth-generation MAGNITUDE Scaffold
  • Table 62: MAGNITUDE Scaffold - Restoring Endoluminal Narrowing Using Bioresorbable Scaffolds - Extended Trial III
  • Table 63: Arterius Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 64: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Status
  • Table 65: Arteriosorb Absorbable Drug-Eluting Scaffold - Product Description
  • Table 66: Biosten, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 67: Biodegradable Endovascular Implant - Product Status
  • Table 68: Biodegradable Endovascular Implant - Product Description
  • Table 69: Biotronik SE & Co. KG Pipeline Products & Ongoing Clinical Trials Overview
  • Table 70: AMS-1 - Product Status
  • Table 71: AMS-1 - Product Description
  • Table 72: AMS-2 - Product Status
  • Table 73: AMS-2 - Product Description
  • Table 74: DREAMS - Product Status
  • Table 75: DREAMS - Product Description
  • Table 76: DREAMS 2G - Product Status
  • Table 77: DREAMS 2G - Product Description
  • Table 78: Biotronik SE & Co. KG - Ongoing Clinical Trials Overview
  • Table 79: DREAMS 2G - BIOTRONIK - Safety and Clinical Performance of the Drug Eluting Absorbable Metal Scaffold (DREAMS 2nd Generation) in the Treatment of Subjects with de Novo Lesions in Native Coronary Arteries: BIOSOLVE-II
  • Table 80: DREAMS 2G - BIOTRONIKS - Acute Performance Of a Drug Eluting Absorbable Metal Scaffold (DREAMS 2G) in Patients with de Novo Lesions in Native Coronary Arteries - BIOSOLVE-III
  • Table 81: Boston Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 82: Fully Resorbable Drug-Eluting Scaffold System - Product Status
  • Table 83: Fully Resorbable Drug-Eluting Scaffold System - Product Description
  • Table 84: Next Generation SYNERGY - Product Status
  • Table 85: Next Generation SYNERGY - Product Description
  • Table 86: Boston Scientific Corporation - Ongoing Clinical Trials Overview
  • Table 87: Next Generation SYNERGY - Comparison Between SYNERGY Versus Bioresorbable Vascular Scaffold (BVS) ABSORB Neointimal Formation Assessed by (Optical Coherence Tomography) OCT and Coronary Angioscopy (CAS) Evaluation (The ENHANCE Study - Endothelial Healing Assessment With Novel Coronary Technology)
  • Table 88: Fully Resorbable Drug-Eluting Scaffold System - Fully Absorbable Scaffold Feasibility Study
  • Table 89: Cardionovum GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 90: ReNATURAL (M) - Product Status
  • Table 91: ReNATURAL (M) - Product Description
  • Table 92: ReNATURAL (P) - Product Status
  • Table 93: ReNATURAL (P) - Product Description
  • Table 94: RESORB - Product Status
  • Table 95: RESORB - Product Description
  • Table 96: HangZhou HuaAn Biotechnology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: Xinsorb BRS - Product Status
  • Table 98: Xinsorb BRS - Product Description
  • Table 99: Icon Interventional Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 100: Biosorb Pediatric Dissolving Stent - Product Status
  • Table 101: Biosorb Pediatric Dissolving Stent - Product Description
  • Table 102: Japan Stent Technology Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 103: Bioabsorbable Stent - Product Status
  • Table 104: Bioabsorbable Stent - Product Description
  • Table 105: Kyoto Medical Planning Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 106: Igaki-Tamai Coronary Stent - Product Status
  • Table 107: Igaki-Tamai Coronary Stent - Product Description
  • Table 108: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 109: Absorbable Coronary Stent - Product Status
  • Table 110: Absorbable Coronary Stent - Product Description
  • Table 111: Medlogics Device Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 112: COBRA-P Drug Eluting Stent - Product Status
  • Table 113: COBRA-P Drug Eluting Stent - Product Description
  • Table 114: Meril Life Sciences Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 115: MeRes100 - Product Status
  • Table 116: MeRes100 - Product Description
  • Table 117: Meril Life Sciences Pvt. Ltd. - Ongoing Clinical Trials Overview
  • Table 118: MeRes100 - A Prospective, Multinational, Multicenter, Single Arm, Open Label, Pilot Clinical Study of MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System in the Treatment of De-novo Native Coronary Artery Lesions (MeRes-1 Extend)
  • Table 119: MicroPort Scientific Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 120: Firefalcon Bioresorbable Device - Product Status
  • Table 121: Firefalcon Bioresorbable Device - Product Description
  • Table 122: NanoCoeur, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 123: Nanocoating Cardiac Stent - Product Status
  • Table 124: Nanocoating Cardiac Stent - Product Description
  • Table 125: North Carolina State University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 126: Biodegradable Metal Stent - Product Status
  • Table 127: Biodegradable Metal Stent - Product Description
  • Table 128: Northwestern University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 129: Liquid Biodegradable Drug Eluting Stent - Product Status
  • Table 130: Liquid Biodegradable Drug Eluting Stent - Product Description
  • Table 131: OrbusNeich Pipeline Products & Ongoing Clinical Trials Overview
  • Table 132: ON-AVS Scaffold - Product Status
  • Table 133: ON-AVS Scaffold - Product Description
  • Table 134: Pegasus Therapeutics, Llc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 135: Bioresorbable Flow Diverter - Product Status
  • Table 136: Bioresorbable Flow Diverter - Product Description
  • Table 137: REVA Medical, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 138: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Status
  • Table 139: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Product Description
  • Table 140: ReZolve2 - Product Status
  • Table 141: ReZolve2 - Product Description
  • Table 142: REVA Medical, Inc. - Ongoing Clinical Trials Overview
  • Table 143: ReZolve2 - RESTORE II Trial: Safety And Performance Study Of The ReZolve2 Sirolimus-Eluting Bioresorbable Coronary Scaffold
  • Table 144: Fantom Sirolimus-Eluting Bioresorbable Scaffold - FANTOM I Clinical Trial
  • Table 145: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Pilot Study of the REVA Sirolimus-Eluting Bioresorbable Coronary Scaffold
  • Table 146: Fantom Sirolimus-Eluting Bioresorbable Scaffold - Safety & Performance Study of the FANTOM Sirolimus-eluting Bioresorbable Coronary Scaffold
  • Table 147: S3V Vascular Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • Table 148: 3V Avatar - Product Status
  • Table 149: 3V Avatar - Product Description
  • Table 150: Shanghai MicroPort Medical Group Co Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 151: Bioresorbable Scaffold System - Product Status
  • Table 152: Bioresorbable Scaffold System - Product Description
  • Table 153: Tepha, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 154: TephaFLEX Absorbable Coronary Stent - Product Status
  • Table 155: TephaFLEX Absorbable Coronary Stent - Product Description
  • Table 156: VasoTech Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 157: PowerStent Absorb DES - Product Status
  • Table 158: PowerStent Absorb DES - Product Description
  • Table 159: PowerStent Coro DES - Product Status
  • Table 160: PowerStent Coro DES - Product Description
  • Table 161: Xenogenics Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 162: Ideal BioStent - First Generation - Product Status
  • Table 163: Ideal BioStent - First Generation - Product Description
  • Table 164: Ideal BioStent - Second Generation - Product Status
  • Table 165: Ideal BioStent - Second Generation - Product Description
  • Table 166: IDEAL Stent - Product Status
  • Table 167: IDEAL Stent - Product Description
  • Table 168: Whisper Coronary Stent System - Product Status
  • Table 169: Whisper Coronary Stent System - Product Description
  • Table 170: Glossary

List of Figures

  • Figure 1: Bioabsorbable Stents (BAS) - Pipeline Products by Stage of Development
  • Figure 2: Bioabsorbable Stents (BAS) - Pipeline Products by Territory
  • Figure 3: Bioabsorbable Stents (BAS) - Pipeline Products by Regulatory Path
  • Figure 4: Bioabsorbable Stents (BAS) - Pipeline Products by Estimated Approval Date
  • Figure 5: Bioabsorbable Stents (BAS) - Ongoing Clinical Trials
Back to Top